Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Executive Summary
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
Topics
- Subjects
- Commercial
- Strategy
- Generic Drugs
- Regions
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC098821
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC098821
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.